{"id":384732,"date":"2020-11-19T06:33:08","date_gmt":"2020-11-19T11:33:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384732"},"modified":"2020-11-19T06:33:08","modified_gmt":"2020-11-19T11:33:08","slug":"avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/","title":{"rendered":"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants<\/b><\/p>\n<p>OTTAWA, Ontario&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAvivagen Inc. (TSXV:VIV) (\u201cAvivagen\u201d or the \u201cCorporation\u201d), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants previously had an expiration date of November 30, 2020, which has been extended to June 30, 2021.\n<\/p>\n<p>\nAll other terms and conditions of the warrants remain unchanged. Avivagen previously announced its intention to seek approval of such extension by way of a press release on November 13, 2020.\n<\/p>\n<p><b>About Avivagen<\/b><\/p>\n<p>\nAvivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of \u03b2-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture and OTCQB<sup>\u00ae<\/sup> Venture Market exchanges under the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avivagen.com&amp;esheet=52331704&amp;newsitemid=20201119005213&amp;lan=en-US&amp;anchor=www.avivagen.com&amp;index=1&amp;md5=7e86aea505ee5b03796bde3373478901\">www.avivagen.com<\/a>. The contents of the website are expressly not incorporated by reference in this press release.\n<\/p>\n<p><b>About OxC-beta\u2122 Technology and OxC-beta\u2122 Livestock<\/b><\/p>\n<p>\nAvivagen\u2019s OxC-beta\u2122 technology is derived from Avivagen discoveries about \u03b2-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta\u2122 Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Australia and Malaysia.\n<\/p>\n<p>\nAvivagen\u2019s OxC-beta\u2122 Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta\u2122 Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.\n<\/p>\n<p style=\"font-weight:normal\"><b>Forward Looking Statements<\/b><\/p>\n<p><i>This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions \u201caim\u201d, \u201canticipate\u201d, \u201cappear\u201d, \u201cbelieve\u201d, \u201cconsider\u201d, \u201ccould\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cif\u201d, \u201cintend\u201d, \u201cgoal\u201d, \u201chope\u201d, \u201clikely\u201d, \u201cmay\u201d, \u201cplan\u201d, \u201cpossibly\u201d, \u201cpotentially\u201d, \u201cpursue\u201d, \u201cseem\u201d, \u201cshould\u201d, \u201cwhether\u201d, \u201cwill\u201d, \u201cwould\u201d and similar expressions. Statements set out in this news release relating to the possibility for OxC-beta\u2122 Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen\u2019s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen\u2019s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen\u2019s most recent management\u2019s discussion and analysis of financial condition available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SEDAR.com&amp;esheet=52331704&amp;newsitemid=20201119005213&amp;lan=en-US&amp;anchor=www.SEDAR.com&amp;index=2&amp;md5=5dcac29b303080dff6775bc97a94cfca\">www.SEDAR.com<\/a>. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.<\/i><\/p>\n<p><i>Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/i><\/p>\n<p>\nCopyright \u00a9 2020 Avivagen Inc. OxC-beta\u2122 is a trademark of Avivagen Inc.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201119005213\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201119005213\/en\/<\/a><\/span><\/p>\n<p><b>For more information:<br \/>\n<\/b><br \/>Avivagen Inc.<br \/>\n<br \/>Drew Basek<br \/>\n<br \/>Director of Investor Relations<br \/>\n<br \/>100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733<br \/>\n<br \/>E-mail: <a rel=\"nofollow\" href=\"mailto:d.basek@avivagen.com\">d.basek@avivagen.com<\/a><\/p>\n<p>\nKym Anthony<br \/>\n<br \/>Chief Executive Officer<br \/>\n<br \/>100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164<br \/>\n<br \/>Website: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avivagen.com%2F&amp;esheet=52331704&amp;newsitemid=20201119005213&amp;lan=en-US&amp;anchor=www.avivagen.com&amp;index=3&amp;md5=46e77875e590c3e1accbd81f9cb95537\">www.avivagen.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Consumer Agriculture Pets Natural Resources Veterinary<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants OTTAWA, Ontario&#8211;(BUSINESS WIRE)&#8211; Avivagen Inc. (TSXV:VIV) (\u201cAvivagen\u201d or the \u201cCorporation\u201d), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants previously had an expiration date of November 30, 2020, which has been extended to June 30, 2021. All other terms and conditions of the warrants remain unchanged. Avivagen previously announced its intention to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384732","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants OTTAWA, Ontario&#8211;(BUSINESS WIRE)&#8211; Avivagen Inc. (TSXV:VIV) (\u201cAvivagen\u201d or the \u201cCorporation\u201d), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants previously had an expiration date of November 30, 2020, which has been extended to June 30, 2021. All other terms and conditions of the warrants remain unchanged. Avivagen previously announced its intention to &hellip; Continue reading &quot;Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T11:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants\",\"datePublished\":\"2020-11-19T11:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/\"},\"wordCount\":763,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/\",\"name\":\"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-19T11:33:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/","og_locale":"en_US","og_type":"article","og_title":"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants - Market Newsdesk","og_description":"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants OTTAWA, Ontario&#8211;(BUSINESS WIRE)&#8211; Avivagen Inc. (TSXV:VIV) (\u201cAvivagen\u201d or the \u201cCorporation\u201d), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange for the extension of the expiration date of warrants exercisable to purchase 2,029,250 common shares at $1.20 per share, which were originally issued on November 30, 2017. These warrants previously had an expiration date of November 30, 2020, which has been extended to June 30, 2021. All other terms and conditions of the warrants remain unchanged. Avivagen previously announced its intention to &hellip; Continue reading \"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T11:33:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants","datePublished":"2020-11-19T11:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/"},"wordCount":763,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/","name":"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-19T11:33:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201119005213r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avivagen-announces-tsx-venture-exchange-approval-for-extension-of-warrants-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384732"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384732\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}